TorreyPines Therapeutics, Inc. has recently completed the second Phase 1 study of its NGX267 in clinical development for the treatment of Alzheimer's disease.
NGX267 is a selective cholinergic muscarinic (or M1) receptor agonist that previously demonstrated potential in providing both symptomatic improvement and disease modification in animal models of Alzheimer's disease which in this study was evaluated for safety, tolerability and pharmacokinetics in healthy elderly volunteers.
More details at TorreyPines Therapeutics, Inc.’s press release.The trial enrolled 26 volunteers at one center in the U.S. Clinical data showed that NGX267 was well tolerated at single doses up to and including 15 mg and that evidence of cholinergic activation was detected at these doses.
Additionally, exposure levels of NGX267 in elderly men and women at doses of 15 mg or lower may be comparable to those levels tested in a transgenic mouse study, published in the journal Neuron (Vol. 49, 671-682) in March of this year.
.jpg)
Comment Preview